Lidocaine (CAS 137-58-6) — formula C14H22N2O, molecular weight 234.34; category organic chemicals.
| CAS Number | 137-58-6 |
|---|---|
| Molecular Formula | C14H22N2O |
| Molecular Weight | 234.34 |
| Melting Point | 68.5 |
| Boiling Point | 159-160 °C at 2.00E+00 mm Hg |
| LogP | 2.44 |
| Applications | Uses: THERAPEUTIC CATEGORY (VETERINARY): Anesthetic (local), MEDICATION, MEDICATION (VET), Anesthetics, Local, Anti-Arrhythmia Agents, Voltage-Gated Sodium Channel Blockers, Use (kg) in Switzerland (2009): >1000, Use (kg, approx.) in Germany (2009): >7500, Use (kg) in USA (2002): 1630, Consumption (g per capita) in Switzerland (2009): 0.13, Consumption (g per capita, approx.) in Germany (2009): 0.092, Consumption (g per capita) in the USA (2002): 0.0058, Excretion rate: 0.1, Calculated removal (%): 10.5, For production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks., Use Classification: Animal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients, Pharmaceuticals -> Nervous System -> Anaesthetics -> Local anaesthetics -> Amides, Pharmaceuticals -> Animal Drugs -> Approved in Taiwan, Methods of Manufacturing: Prepared by acylation of 2, 6-dimethylaniline with chloroacetyl chloride and subsequent reaction with diethylamine., By action of diethylamine on chloroacetylxylidide., Preparation: N. M. Lofgren, B. J. Lundqvist, United States of America patent 2441498 (1948 to Astra), A. D. H. Self, A. P. T. Easson, United Kingdom patent 706409 (1954 to May & Baker), I. P. S. Hardie, E. S. Stern, United Kingdom patent 758224 (1956 to J. F. MacFarlane & Co.), ... Synthesized by reacting 2, 6-dimethylaniline with chloroacetyl chloride in glacial acetic acid and adding sodium acetate. The product (chloroacetyl-2, 6-dimethylanilide) is boiled with diethylamine in an inert solvent (e.g., benzene). The hydrochloride crystallizes with one molecule of water which can be removed by careful drying., Lidocaine hydrochloride, Formulations, Preparations: Table: Lidocaine Hydrochloride Preparations [Table#4541], Table: Lidocaine Hydrochloride in Dextrose Preparations [Table#4542], Table: Lidocaine Hydrochloride in Dextrose Preparations [Table#4543], Table: Lidocaine Hydrochloride Preparations [Table#4544], For more Formulations, Preparations (Complete) data for LIDOCAINE (7 total), please visit the HSDB record page., General Manufacturing Information: Acetamide, 2-(diethylamino)-N-(2, 6-dimethylphenyl)-: ACTIVE, List of Essential Medicines: The core list presents a list of minimum medicine needs for a basic health-care system, listing the most efficacious, safe and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment. Lidocaine is included on this list., ... Synthetic nonnarcotic substitutes for cocaine, the first anesthetic ever used. ... Lidocaine is preferred in veterinary medicine. |
| Category | Organic Chemicals |
Documented applications: Uses: THERAPEUTIC CATEGORY (VETERINARY): Anesthetic (local), MEDICATION, MEDICATION (VET), Anesthetics, Local, Anti-Arrhythmia Agents, Voltage-Gated Sodium Channel Blockers, Use (kg) in Switzerland (2009): >1000, Use (kg, approx.) in Germany (2009): >7500, Use (kg) in USA (2002): 1630, Consumption (g per capita) in Switzerland (2009): 0.13, Consumption (g per capita, approx.) in Germany (2009): 0.092, Consumption (g per capita) in the USA (2002): 0.0058, Excretion rate: 0.1, Calculated removal (%): 10.5, For production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks., Use Classification: Animal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients, Pharmaceuticals -> Nervous System -> Anaesthetics -> Local anaesthetics -> Amides, Pharmaceuticals -> Animal Drugs -> Approved in Taiwan, Methods of Manufacturing: Prepared by acylation of 2, 6-dimethylaniline with chloroacetyl chloride and subsequent reaction with diethylamine., By action of diethylamine on chloroacetylxylidide., Preparation: N. M. Lofgren, B. J. Lundqvist, United States of America patent 2441498 (1948 to Astra), A. D. H. Self, A. P. T. Easson, United Kingdom patent 706409 (1954 to May & Baker), I. P. S. Hardie, E. S. Stern, United Kingdom patent 758224 (1956 to J. F. MacFarlane & Co.), ... Synthesized by reacting 2, 6-dimethylaniline with chloroacetyl chloride in glacial acetic acid and adding sodium acetate. The product (chloroacetyl-2, 6-dimethylanilide) is boiled with diethylamine in an inert solvent (e.g., benzene). The hydrochloride crystallizes with one molecule of water which can be removed by careful drying., Lidocaine hydrochloride, Formulations, Preparations: Table: Lidocaine Hydrochloride Preparations [Table#4541], Table: Lidocaine Hydrochloride in Dextrose Preparations [Table#4542], Table: Lidocaine Hydrochloride in Dextrose Preparations [Table#4543], Table: Lidocaine Hydrochloride Preparations [Table#4544], For more Formulations, Preparations (Complete) data for LIDOCAINE (7 total), please visit the HSDB record page., General Manufacturing Information: Acetamide, 2-(diethylamino)-N-(2, 6-dimethylphenyl)-: ACTIVE, List of Essential Medicines: The core list presents a list of minimum medicine needs for a basic health-care system, listing the most efficacious, safe and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment. Lidocaine is included on this list., ... Synthetic nonnarcotic substitutes for cocaine, the first anesthetic ever used. ... Lidocaine is preferred in veterinary medicine..
Lidocaine is a carbon-based organic compound with CAS registry number 137-58-6 and molecular formula C14H22N2O (molecular weight 234.34), belonging to the organic chemicals segment of chemical raw materials.
CAS number: 137-58-6
Its molecular formula C14H22N2O comprises 14 C, 22 H, 2 N, 1 O atoms.
Also known as: Lidocaine · 利多卡因
Category: organic chemicals
The CAS registry number of Lidocaine is 137-58-6.
Molecular formula C14H22N2O, molecular weight 234.34.
It is also registered under: Lidocaine, 利多卡因.
Recorded applications: Uses: THERAPEUTIC CATEGORY (VETERINARY): Anesthetic (local), MEDICATION, MEDICATION (VET), Anesthetics, Local, Anti-Arrhythmia Agents, Voltage-Gated Sodium Channel Blockers, Use (kg) in Switzerland (2009): >1000, Use (kg, approx.) in Germany (2009): >7500, Use (kg) in USA (2002): 1630, Consumption (g per capita) in Switzerland (2009): 0.13, Consumption (g per capita, approx.) in Germany (2009): 0.092, Consumption (g per capita) in the USA (2002): 0.0058, Excretion rate: 0.1, Calculated removal (%): 10.5, For production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks., Use Classification: Animal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients, Pharmaceuticals -> Nervous System -> Anaesthetics -> Local anaesthetics -> Amides, Pharmaceuticals -> Animal Drugs -> Approved in Taiwan, Methods of Manufacturing: Prepared by acylation of 2, 6-dimethylaniline with chloroacetyl chloride and subsequent reaction with diethylamine., By action of diethylamine on chloroacetylxylidide., Preparation: N. M. Lofgren, B. J. Lundqvist, United States of America patent 2441498 (1948 to Astra), A. D. H. Self, A. P. T. Easson, United Kingdom patent 706409 (1954 to May & Baker), I. P. S. Hardie, E. S. Stern, United Kingdom patent 758224 (1956 to J. F. MacFarlane & Co.), ... Synthesized by reacting 2, 6-dimethylaniline with chloroacetyl chloride in glacial acetic acid and adding sodium acetate. The product (chloroacetyl-2, 6-dimethylanilide) is boiled with diethylamine in an inert solvent (e.g., benzene). The hydrochloride crystallizes with one molecule of water which can be removed by careful drying., Lidocaine hydrochloride, Formulations, Preparations: Table: Lidocaine Hydrochloride Preparations [Table#4541], Table: Lidocaine Hydrochloride in Dextrose Preparations [Table#4542], Table: Lidocaine Hydrochloride in Dextrose Preparations [Table#4543], Table: Lidocaine Hydrochloride Preparations [Table#4544], For more Formulations, Preparations (Complete) data for LIDOCAINE (7 total), please visit the HSDB record page., General Manufacturing Information: Acetamide, 2-(diethylamino)-N-(2, 6-dimethylphenyl)-: ACTIVE, List of Essential Medicines: The core list presents a list of minimum medicine needs for a basic health-care system, listing the most efficacious, safe and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment. Lidocaine is included on this list., ... Synthetic nonnarcotic substitutes for cocaine, the first anesthetic ever used. ... Lidocaine is preferred in veterinary medicine..
Category: Organic Chemicals.
Independent reference data for Lidocaine (CAS 137-58-6), compiled from public chemistry databases.
| CAS Registry Number | 137-58-6 |
|---|---|
| PubChem CID | 3676 |
| Molecular formula | C14H22N2O |
| IUPAC name | 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide |
| UNII (FDA) | 98PI200987 |
| Molecular Weight | 234.34 |
|---|---|
| XLogP3 | 2.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 5 |
| Exact Mass | 234.173213330 |
| Monoisotopic Mass | 234.173213330 |
| Topological Polar Surface Area | 32.3 |
| Heavy Atom Count | 17 |
| Boiling Point | 159-160 °C at 2.00E+00 mm Hg |
|---|---|
| Boiling Point | BP: 180-182 °C at 4 mm Hg; 159-160 °C at 2 mm Hg |
| Boiling Point | 181 °C |
| Melting Point | 68.5 |
| Melting Point | 68 °C |
| Melting Point | 68.5 °C |
| Solubility | 4100 |
| Solubility | In water, 410 mg/L at 30 °C |
| Solubility | 5.93e-01 g/L |
| LogP | 2.44 |
lidocaine; 137-58-6; Xylocaine; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; Duncaine; Lidoderm; Xylestesin; Esracaine; Gravocain; Isicaina; Leostesin; Maricaine; Solcain; Cappicaine; Solarcaine; Isicaine
| GHS notification summary | 1.2% (2 / 167) |
|---|
| GHS notification summary | 1.2% (2 / 167) |
|---|---|
| Reported hazard statements | H302 (98.2%), H317, H362, H370, H372 |
This chemical does not meet GHS hazard criteria for 1.2% (2 of 167) of reports.
H302 (98.2%): Harmful if swallowed [Warning Acute toxicity, oral]
Lidocaine · CAS 137-58-6 · C14H22N2O. UNII 98PI200987. Boiling Point: 159-160 °C at 2.00E+00 mm Hg; Boiling Point: BP: 180-182 °C at 4 mm Hg; 159-160 °C at 2 mm Hg; Boiling Point: 181 °C.
Source: PubChem / Wikidata; the batch COA governs where values differ.
Supplier: Jinan Shenghe Chemical Co., Ltd.
中文页面: 利多卡因